Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy
Bull Cancer. 2024 Mar 28:S0007-4551(24)00080-8. doi: 10.1016/j.bulcan.2024.01.011. Online ahead of print.NO ABSTRACTPMID:38553285 | DOI:10.1016/j.bulcan.2024.01.011
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Charl ène Rivier Pernelle Lavaud Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer